Long-term Outcomes of Contemporary Coronary Revascularization by Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in Young Adults.


Journal

The Israel Medical Association journal : IMAJ
ISSN: 1565-1088
Titre abrégé: Isr Med Assoc J
Pays: Israel
ID NLM: 100930740

Informations de publication

Date de publication:
Dec 2019
Historique:
entrez: 10 12 2019
pubmed: 10 12 2019
medline: 18 12 2019
Statut: ppublish

Résumé

Current guidelines for choosing between revascularization modalities may not be appropriate for young patients. To compare outcomes and guide treatment options for patients < 40 years of age, who underwent percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) between 2008 and 2018. Outcomes were compared for 183 consecutive patients aged < 40 years who underwent PCI or CABG between 2008 and 2018, Outcomes were compared as time to first event and as cumulative events for non-fatal outcomes. Mean patient age was 36.3 years and 96% were male. Risk factors were similar for both groups. Drug eluting stents were implemented in 71% of PCI patients and total arterial revascularization in 74% of CABG patients. During a median follow-up of 6.5 years, 16 patients (8.6%) died. First cardiovascular events occurred in 35 (38.8%) of the PCI group vs. 29 (31.1%) of the CABG group (log rank P = 0.022), repeat events occurred in 96 vs. 51 (P < 0.01), respectively. After multivariate adjustment, CABG was associated with a significantly reduced risk for first adverse event (hazard ratio [HR] 0.305, P < 0.01) caused by a reduction in repeat revascularization. CABG was also associated with a reduction in overall repeat events (HR 0.293, P < 0.01). There was no difference in overall mortality between CABG and PCI. Young patients with coronary disease treated by CABG showed a reduction in the risk for non-fatal cardiac events. Mortality was similar with CABG and PCI.

Sections du résumé

BACKGROUND BACKGROUND
Current guidelines for choosing between revascularization modalities may not be appropriate for young patients.
OBJECTIVES OBJECTIVE
To compare outcomes and guide treatment options for patients < 40 years of age, who underwent percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) between 2008 and 2018.
METHODS METHODS
Outcomes were compared for 183 consecutive patients aged < 40 years who underwent PCI or CABG between 2008 and 2018, Outcomes were compared as time to first event and as cumulative events for non-fatal outcomes.
RESULTS RESULTS
Mean patient age was 36.3 years and 96% were male. Risk factors were similar for both groups. Drug eluting stents were implemented in 71% of PCI patients and total arterial revascularization in 74% of CABG patients. During a median follow-up of 6.5 years, 16 patients (8.6%) died. First cardiovascular events occurred in 35 (38.8%) of the PCI group vs. 29 (31.1%) of the CABG group (log rank P = 0.022), repeat events occurred in 96 vs. 51 (P < 0.01), respectively. After multivariate adjustment, CABG was associated with a significantly reduced risk for first adverse event (hazard ratio [HR] 0.305, P < 0.01) caused by a reduction in repeat revascularization. CABG was also associated with a reduction in overall repeat events (HR 0.293, P < 0.01). There was no difference in overall mortality between CABG and PCI.
CONCLUSIONS CONCLUSIONS
Young patients with coronary disease treated by CABG showed a reduction in the risk for non-fatal cardiac events. Mortality was similar with CABG and PCI.

Identifiants

pubmed: 31814346

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

817-822

Auteurs

Dror B Leviner (DB)

Department of Cardiothoracic Surgery, Carmel Medical Center, Haifa, Israel.

Guy Witberg (G)

Department of Cardiology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.

Amir Sharon (A)

Department of Cardiothoracic Surgery, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.

Yosif Boulos (Y)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Alon Barsheshet (A)

Department of Cardiology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.

Erez Sharoni (E)

Department of Cardiothoracic Surgery, Carmel Medical Center, Haifa, Israel.

Dan Spiegelstein (D)

Department of Cardiothoracic Surgery, Carmel Medical Center, Haifa, Israel.

Hana Vaknin-Assa (H)

Department of Cardiology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.

Dan Aravot (D)

Department of Cardiothoracic Surgery, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.

Ran Kornowski (R)

Department of Cardiology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.

Abid Assali (A)

Department of Cardiology, Rabin Medical Center (Beilinson Campus), Petah Tikva, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH